CEPHALON ALS DRUG IS JUNE HIT; GRAND SLAM IF SECOND TRIAL IS POSITIVE
Executive Summary
Cephalon stock ended June up 8-3/4 points, or 89.7%, with backing from data on the first of two pivotal trials of its Lou Gehrig's disease therapy Myotrophin. The study that could bring the drug home to approval will be completed this summer in Europe, and a PLA could be filed by year-end if results of that second, 183-patient Phase III trial are similarly positive